Efficacy and Safety of Ranibizumab With or Without Laser in Comparison to Laser in Branch Retinal Vein Occlusion

Inclusion Criteria: * Written informed consent must be obtained before any study assessment is performed * Diagnosis of visual impairment exclusively due to ME secondary to BRVO * BCVA score at Screening and Baseline between 73 and 19 letters (ETDRS) Exclusion Criteria: * Pregnant or nursing (lactating) women * Stroke or myocardial infarction less than 3 months before Screening * Uncontrolled blood pressure defined as systolic value of \>160 mm Hg or diastolic value of \>100 mm Hg at Screening or Baseline. * Any active periocular or ocular infection or inflammation at Screening or Baseline in either eye * Uncontrolled glaucoma at Screening or Baseline or diagnosed within 6 months before Baseline in either eye * Neovascularization of the iris or neovascular glaucoma in the study eye * Use of any systemic antivascular endothelial growth factor (anti-VEGF) drugs within 6 months before Baseline * Panretinal laser photocoagulation within 3 months before Baseline or anticipated or scheduled within the next 3 months following Baseline in the study eye * Focal or grid laser photocoagulation within 4 months before Baseline in the study eye * Use of intra- or periocular corticosteroids (including sub-Tenon) within 3 months before Screening in the study eye * Any use of intraocular corticosteroid implants (eg, dexamethasone \[Ozurdex®\], fluocinolone acetonide \[Iluvien®\]) in the study eye